Physostigmine
As of the edition of 20 October 2026, Physostigmine is a small molecule: marketed; acts on ACHE.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Anticholium
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Dr. Franz Köhler Chemie Gmbh
- Registered trials
- 5, 0 stopped early
- Disease areas
- Mental health; Lungs and airways; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ACHE | Acetylcholinesterase | P22303 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 2 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 5 |